Licenses; Exemptions, Applications, Amendments etc.: Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies

TitleLicenses; Exemptions, Applications, Amendments etc.: Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies
ToC Doc Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies
Docket Number2022-04829
Type Notice
Subject Licenses; Exemptions, Applications, Amendments etc.:
Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies
Publication Date2022-03-08
Last Updated Date 2022-03-07 08:15:08 -0500
Last Public Inspection2022-03-07
Filed At2022-03-07T08:45:00.000-05:00
PDF 2022-04829_PI.pdf (89627 bytes)
Download TXT / HTML / JSON
Number of Pages 3
Filing Typeregular
AgenciesNational Institutes of Health

You can find the raw source document below...

This site's data is aggregated programmatically and provided "as is" without any representations or warranties, express or implied. OFR.report is not affiliated with the Office of the Federal Register or the US government in any way.

© OFR.report 2021